SCHEMBL222677

SCHEMBL222677

O=[N+]([O-])n1cc(Br)cn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4561818 0.74
SCHEMBL2454457 0.74 F2 (0.45)
SCHEMBL28420162 0.74
SCHEMBL28424145 0.69 VCAM1 (0.38)
SCHEMBL6155504 0.65 HTT (0.47)
SCHEMBL19992719 0.59
SCHEMBL28879327 0.57
SCHEMBL937 0.56
SCHEMBL27928753 0.52
SCHEMBL651428 0.47 MEN1 (0.75)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111235597-B Synthesis method of nitroazole energetic compound 南京理工大学 2020-10-30 CN disclosed
CN-111235597-A Synthesis method of nitroazole energetic compound 南京理工大学 2020-06-05 CN disclosed
EP-2508182-B1 Hydralazine for use in the treatment of age-related macular degeneration TEXAS A & M UNIV SYS (US) 2016-07-06 EP disclosed
EP-2508183-B1 Interleukin-1 blocker for use in the treatment of age-related macular degeneration TEXAS A & M UNIV SYS (US) 2014-07-09 EP disclosed
US-20130059841-A1 THERAPEUTIC COMPOSITIONS AND METHODS THE TEXAS A&M UNIVERSITY SYSTEM (US) 2013-03-07 US disclosed
US-20130059841-A1 THERAPEUTIC COMPOSITIONS AND METHODS THE TEXAS A&M UNIVERSITY SYSTEM (US) 2013-03-07 US disclosed
US-8318741-B2 Therapeutic compositions and methods THE TEXAS A & M UNIVERSITY SYSTEM (US) 2012-11-27 US disclosed
US-8318741-B2 Therapeutic compositions and methods THE TEXAS A & M UNIVERSITY SYSTEM (US) 2012-11-27 US disclosed
EP-2508182-A1 Hydralazine for use in the treatment of age-related macular degeneration THE TEXAS A & M UNIVERSITY SYSTEM (US) 2012-10-10 EP disclosed
EP-2508182-A1 Hydralazine for use in the treatment of age-related macular degeneration THE TEXAS A & M UNIVERSITY SYSTEM (US) 2012-10-10 EP disclosed
US-20120196868-A1 THERAPEUTIC COMPOSITIONS AND METHODS THE TEXAS A&M UNIVERSITY SYSTEM (US) 2012-08-02 US disclosed
US-20120115959-A1 Therapeutic Compositions And Methods THE TEXAS A&M UNIVERSITY SYSTEM 2012-05-10 US disclosed
US-20120115959-A1 Therapeutic Compositions And Methods THE TEXAS A&M UNIVERSITY SYSTEM 2012-05-10 US disclosed
US-20120071485-A1 Therapeutic Compositions And Methods THE TEXAS A&M UNIVERSITY SYSTEM 2012-03-22 US disclosed
US-20120071485-A1 Therapeutic Compositions And Methods THE TEXAS A&M UNIVERSITY SYSTEM 2012-03-22 US disclosed
US-8088773-B2 Therapeutic compositions and methods THE TEXAS A&M UNIVERSITY SYSTEM (US) 2012-01-03 US disclosed
US-8088773-B2 Therapeutic compositions and methods THE TEXAS A&M UNIVERSITY SYSTEM (US) 2012-01-03 US disclosed
EP-1885371-A1 THERAPEUTIC COMPOSITIONS AND METHODS The Texas A &amp; M University System (US) 2008-02-13 EP disclosed
US-20060276458-A1 Therapeutic compositions and methods THE TEXAS A & M UNIVERSITY SYSTEM 2006-12-07 US disclosed
WO-2006124324-A1 THERAPEUTIC COMPOSITIONS AND METHODS THE TEXAS A & M UNIVERSITY SYSTEM (US) 2006-11-23 WO disclosed